This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignees: Enantis S.r.o., Masarykova Univerzita. Active years: 2023.
Company Filing History:
1 out of 1 
1 out of 15 Years Active: 2023
Title: Pavel Dvorak: Innovator in Thermostable Polypeptides
Introduction
Pavel Dvorak is a notable inventor based in Brno, Czech Republic. He has made significant contributions to the field of cell biology and regenerative medicine through his innovative research and patents. His work focuses on the development of thermostable polypeptides, which have important applications in various medical and cosmetic fields.
Latest Patents
Dvorak holds a patent for a thermostable FGF2 polypeptide, which is characterized by its isolated nature and FGF2 activity. This polypeptide exhibits at least 85% sequence identity to SEQ ID NO: 2 (FGF2 wt) and includes at least one amino acid substitution, specifically R31L. The invention is particularly valuable for cell biology research, regenerative medicine, and related medical applications or cosmetics. Additionally, it discloses a culture medium that incorporates the subjected FGF2, making it suitable for culturing human pluripotent stem cells, including both human embryonic stem cells and induced pluripotent stem cells.
Career Highlights
Throughout his career, Pavel Dvorak has worked with esteemed institutions such as Masaryk University and Enantis s.r.o. His research has been pivotal in advancing the understanding and application of polypeptides in scientific and medical contexts.
Collaborations
Dvorak has collaborated with notable colleagues, including David Bednar and Michaela Bosakova. Their combined expertise has contributed to the success of his research endeavors.
Conclusion
Pavel Dvorak's innovative work in the field of thermostable polypeptides exemplifies the impact of scientific research on medicine and biotechnology. His contributions continue to influence advancements in regenerative medicine and cell biology.